ArticleBreast cancer research : BCR2005
Immunohistochemical evaluation of human epidermal growth factor receptor 2 and estrogen and progesterone receptors in breast carcinoma in Jordan.
Article in Breast cancer research : BCR, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 99 citations in OpenAlex.
- Tumor characteristics and survival rate of axillary metastatic breast cancer patients: a three decades retrospective cohort study.Scientific reports · 2025Article
- Glutamate metabotropic receptor 4 in breast cancer: a potential and specific target for chimeric antigen receptor therapy.Frontiers in oncology · 2025Article
- Unveiling HER2 immunoexpression in canine hepatoid gland neoplasms: clinicopathological and morphological associations.International journal of veterinary science and medicine · 2025Article
- «Salivaomics» of Different Molecular Biological Subtypes of Breast Cancer.Current issues in molecular biology · 2022Article
- Assessment of breast cancer immunohistochemistry and tumor characteristics in Nigeria.World journal of clinical oncology · 2020Article
- Comparison of the efficacy and survival analysis of neoadjuvant chemotherapy for Her-2-positive breast cancer.Drug design, development and therapy · 2018Article
- A nomogram to predict HER2 status in breast cancer patients with HER2-borderline disease as determined via immunohistochemistry.Oncotarget · 2017Article
- First report on molecular breast cancer subtypes and their clinico-pathological characteristics in Eastern Morocco: series of 2260 cases.BMC women's health · 2017Article
- Postmenopausal Breast Cancer Risk in Relation to Antibodies Specific to Benzo[a]Pyrene, Estradiol and Progesterone.Iranian journal of cancer prevention · 2016Article
- Efficacy of TCH/TEC neoadjuvant chemotherapy for the treatment of HER-2-overexpressing breast cancer.Oncology letters · 2015Article
- The clinical significance of PR, ER, NF- κ B, and TNF- α in breast cancer.Disease markers · 2014Article
- Immunohistochemical evaluation of human epidermal growth factor receptor 2 and estrogen and progesterone receptors in invasive breast cancer in women.Archives of medical science : AMS · 2013Article
- Estrogen receptor, progesterone receptor, and Her 2 Neu positivity and its association with tumour characteristics and menopausal status in a breast cancer cohort from northern Pakistan.Ecancermedicalscience · 2012Article
- Article
- Automation of immunohistochemical evaluation in breast cancer using image analysis.World journal of clinical oncology · 2011Article
- Immunohistochemical detection of phospho-Akt, phospho-BAD, HER2 and oestrogen receptors alpha and beta in Malaysian breast cancer patients.Pathology oncology research : POR · 2010Article
- Datamining approach for automation of diagnosis of breast cancer in immunohistochemically stained tissue microarray images.The open medical informatics journal · 2010Article
- Serum sFas and tumor tissue FasL negatively correlated with survival in Egyptian patients suffering from breast ductal carcinoma.Pathology oncology research : POR · 2009Article
- Detection of HER-2/neu, c-myc amplification and p53 inactivation by FISH in Egyptian patients with breast cancer.German medical science : GMS e-journal · 2009Article
- Correlation of HER-2 over-expression with clinico-pathological parameters in Tunisian breast carcinoma.World journal of surgical oncology · 2008Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionAlthough breast carcinoma (BC) is the most common malignancy affecting Jordanian females and the affected population in Jordan is younger than that in the West, no information is available on its biological characteristics. Our aims in this study are to evaluate the expression of estrogen receptor (ER) and progesterone receptor (PR) and Her-2/neu overexpression in BC in Jordan, and to compare the expression of these with other prognostic parameters for BC such as histological type, histological grade, tumor size, patients' age, and number of lymph node metastases.
methodThis is a retrospective study conducted in the Department of Pathology at Jordan University of Science and Technology. A confirmed 91 cases of BC diagnosed in the period 1995 to 1998 were reviewed and graded. We used immunohistochemistry to evaluate the expression of ER, PR, and Her-2. Immunohistochemical findings were correlated with age, tumor size, grade and axillary lymph node status.
resultsHer-2 was overexpressed in 24% of the cases. The mean age of Her-2 positive cases was 42 years as opposed to 53 years among Her-2 negative cases (p = 0.0001). Her-2 expression was inversely related to ER and PR expression. Her-2 positive tumors tended to be larger than Her-2 negative tumors with 35% overexpression among T3 tumors as opposed to 22% among T2 tumors (p = 0.13). Her-2 positive cases tended to have higher rates of axillary metastases, but this did not reach statistical significance. ER and PR positive cases were seen in older patients with smaller tumor sizes.
conclusionHer-2 overexpression was seen in 24% of BC affecting Jordanian females. Her-2 overexpression was associated with young age at presentation, larger tumor size, and was inversely related to ER and PR expression. One-fifth of the carcinomas were Her-2 positive and ER negative. This group appears to represent an aggressive form of BC presenting at a young age with large primary tumors and a high rate of four or more axillary lymph node metastases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.